DRAFT

Chronology of FDA Interactions
Re: glucose, triglycerides and pancreatitis

Prepared by: Michele Sharp
April 24, 2003

September 13, 1999	Lilly received request from FDA to include pancreatitis in Postintroduction Reports section of Zyprexa USPI.
December 7, 1999	Lilly responded to Sept 1999 FDA labeling request indicating that the data do not support inclusion of pancreatitis in labeling, but would continue to monitor adverse event reports.
February 4, 2000	FDA communicated agreement with Dec 1999 response.
May 9, 2000	Lilly submitted revised Zyprexa USPI with addition of random blood glucose measures in Laboratory Changes section and diabetic coma in Postintroduction Reports section.
May 10, 2000	Lilly received FDA letter dated May 1, 2000 requesting extensive safety information on hyperglycemia, new onset diabetes, non-ketotic hyperosmolar coma, diabetic ketoacidosis and weight gain from preclinical, clinical, and postmarketing sources.
July 31, 2000	Lilly submitted response to May 1, 2000 FDA request.
October 20, 2000	Lilly received FDA letter dated October 11, 2000 regarding label change submitted May 9, 2000 indicating agreement with inclusion of diabetic coma in label and requesting deletion of random blood glucose measures under Laboratory Changes section.
November 29, 2000	Lilly submitted revised Zyprexa USPI with random blood glucose measures deleted from Laboratory Changes section.
May 21, 2001	Lilly submitted additional glucose data (ie PCS, GPRD, manuscript of additional clinical trial analyses) as follow-up to July 31, 2000 submission.
May 25, 2001	Lilly received FDA approval letter regarding November 29, 2000 label revision.
September 6, 2001	Lilly submitted F1D-MC-HGIM clinical study report to IND 28,705.

Confidential

January 11, 2002	Lilly submitted revised Zyprexa USPI with triglyceride information under Laboratory Changes section and pancreatitis under Postintroduction Reports section.
April 12, 2002	Lilly submitted report on Japan hyperglycemia cases.
October 2, 2002	Lilly submitted briefing document to support meeting scheduled with FDA for October 17, 2002.
October 15, 2002	FDA contacted Lilly to cancel October 17, 2002 meeting because FDA was not ready to fully respond questions Lilly raised in briefing document.
November 6, 2002	Lilly submitted F1D-MC-S013 clinical study report to IND 28,705.
January 10, 2003	Lilly received FDA approvable letter indicating agreement with inclusion of pancreatitis in label and requesting deletion of triglyceride information under Laboratory Changes section.
March 6, 2003	Lilly submitted revised Zyprexa USPI in response to January 10, 2003 approvable letter.
March 28, 2003	Lilly submitted updated analyses on postmarketing adverse event reports as follow-up to October 2, 2002 data submission.